Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge to emerging therapies ...

I am a principal correspondent with the national political bureau of the Hindustan Times. I track the aviation and railways ministry. I also write on travel trends. I cover the beats at the ...

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor ...

Love for reading roused Neha’s writing instincts. After completing Masters in Journalism & Mass Communication, her feelings for words only grew. Excuse Neha for being a grammar nerd with an ...

As the contestants prepare for the vote-outs, Harsh accuses Hartaj of betrayal, and Neha backs the claim, calling Hartaj double-faced. Then comes Rannvijay's game-changing twist - Gang Leaders can ...

Arvind SmartSpaces Ltd. is a Public Limited Listed company incorporated on 26/12/2008 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is ...